Vion Pharmaceuticals Announces FDA Lift Of Clinical Hold On Phase III Study Of Cloretazine(R) (VNP40101M) And ... (Medical News Today)
VION PHARMACEUTICALS, INC. (Nasdaq: VION) announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on the Phase III trial (Vion Study CLI-037) of its lead anti-cancer agent, Cloretazine(R) (VNP40101M), in combination with cytarabine in relapsed acute myelogenous leukemia (AML).

Pennington Biomedical Research Institute Receives FDA Approval To Begin Phase I Studies Of Compellis Pharmaceuticals' ... (Medical News Today)
Compellis Pharmaceuticals, an early stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced that its collaborator Pennington Biomedical Research Institute at Louisiana State University, with Principal Investigator Dr. Frank Greenway, MD, has received FDA approval to begin human clinical Phase I studies.

Can-Fite Receives FDA Approval To Conduct Phase I Study With CF102 (Medical News Today)
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, is making progress with CF102, the drug it develops for the treatment of liver cancer. Can-Fite reported that an approval was granted by the Food and Drug Administration (FDA) to conduct a phase I study with its second pipeline drug, CF102.